gray cap, Bivalent/drew up the entire vial and given to patient/Dose administered today was 1.8ml, but it should have been 0.3ml; Product administration error; This is a spontaneous report received from contactable reporter(s) (Nurse) from medical information team.  A 15-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Mar2023 at 16:00 as dose 3 (booster), 1.8 ml single (Lot number: GL0447) at the age of 15 years intramuscular, in arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose 1, single, Batch/Lot no: EW0186), administration date: 26May2021, for COVID-19 immunisation; BNT162b2 (Dose 2, single, Batch/Lot no: EW0186), administration date: 18Jun2021, for COVID-19 immunisation. The following information was reported: PRODUCT ADMINISTRATION ERROR (medically significant) with onset 06Mar2023 at 16:00; OVERDOSE (medically significant) with onset 06Mar2023 at 16:00, described as "gray cap, Bivalent/drew up the entire vial and given to patient/Dose administered today was 1.8ml, but it should have been 0.3ml". Clinical course: Nurse manager calling regarding Pfizer-BioNTech COVID-19 Vaccine, gray cap, Bivalent, HCP reported that nurse drew up the entire vial and given to patient (patient 15 years old, male) asking for next steps based on the situation. Marking duplicate AE (HCP was warm transferred to safety, reportum# withheld. Technical issue sending fulfillment, after several tries issue resolved. Callback 06Mar20235:24PM verified with HCP that requested email was received. HCP appreciated follow up. injection in arm (unknown which arm). physical and getting routine vaccine. Investigations: No. Patient received BioNtech COVID-19 vaccine, gray cap 12 and up bivalent a Pfizer product. Nurse manager calling about AE with Pfizer Biontech COVID-19 vaccine, gray cap 12 and up bivalent. The entire vial was drawn up and administered to a 15 year old male patient. Agent addressed inquiry about next steps. Confirms she is a registered nurse upon transfer. He just had his physical. HCP: he does not have direct line, provides the main line number. When asking for lot number, states her eyes are not the best but then is able to provide lot number. She will not be able to provide NDC by looking at the vial. She has to pull up NDC on the computer and then is not able to locate it. Manufacture date: Aug2022. Expiration: unknown, they have always been told its 18 months past manufacturing date. Dose administered today was 1.8ml, but it should have been 0.3ml. This occurred today at 16:00. This was the patients first booster dose. Pfizer/BioNTech COVID-19 Vaccine Follow-up Questionnaire. Pfizer/BioNtech COVID-19 Vaccine Details: First dose: Pfizer COVID vaccine (SARS COV2 vaccine) administered on 26May2021. Lot: EW0186. NDC/Expiration: unknown received at outside facility. Second dose: Pfizer COVID vaccine (SARS COV2 vaccine) administered on 18Jun2021. Lot: EW0186 (confirms same lot number as first dose) NDC/Expiration: unknown received at outside facility. For Only: Vaccination Facility Type: Primary Care Physicians office. Not Vaccine Administered at Military Facility. Vaccination Facility Address: Facility Name: withheld. Prior Vaccinations (within 4 weeks): No. Family Medical History Relevant to Adverse Events (AEs): unknown. Specific Relevant Test: For Thromboembolic events with Thrombocytopenia: n/a. Adverse Events: AE required visit to: Emergency Room: No; Physician Office: No, patient had left and physician will be reaching out to family of the patient. Treatment: No. Autopsy Information: N/A. Still has not received email regarding various doses or overdose. Product strength and count size dispensed: Pfizer Biontech COVID-19 vaccine, gray cap 12 and up bivalent, 1.8ml. Additional lot numbers: n/a. Is a sample of the product available to be returned, if requested (Y/N): n/a. Packaging sealed and intact:n/a; Sender's Comments: Based on available information, a possible contributory role of  subject  vaccine cannot be excluded for the reported events, based on temporal relationship.. There is  limited information provided in this report.  This case will be reassessed upon receipt of follow-up information.